Home Newsfeeds BTIG Initiates Coverage On Embecta with Neutral Rating

BTIG Initiates Coverage On Embecta with Neutral Rating

BTIG analyst Marie Thibault initiates coverage on Embecta (NASDAQ:EMBC) with a Neutral rating.

byBenzinga Newsdesk

September 8, 2022

1 minute read

BTIG analyst Marie Thibault initiates coverage on Embecta (NASDAQ:EMBC) with a Neutral rating.

Aprea Unveils Initial Clinical Data On ATRi, ATRN-119, And Pre-Clinical Data On WEE1i, ATRN-1051, At AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

By Benzinga Newsdesk

October 16, 8:45 AM

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced highlights of two posters

APRE

Entrada Therapeutics Announces Clinical Hold On IND Application For ENTR-601-44 In Duchenne Muscular Dystrophy

By Benzinga Newsdesk

December 19, 5:37 PM

Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of

TRDA

‘The Big Short’ Star Michael Burry Says SEC Doesn’t Have ‘The Resources Or IQ Point’s To ‘Correctly’ Investigate Coinbase

By Samyuktha Sriram

July 27, 3:35 AM

‘The Big Short’ investor Michael Burry isn’t convinced that the U.S. Securities and Exchange Commission (SEC) can carry out a proper investigation into crypto exchange Coinbase Global Inc (NASDAQ: COIN).

BTC

Here’s How Much $100 Invested In Itau Unibanco Holding 20 Years Ago Would Be Worth Today

By Benzinga Insights

October 31, 2:55 PM

Itau Unibanco Holding (NYSE:ITUB) has outperformed the market over the past 20 years by 3.09% on an annualized basis producing an average annual return of 10.61%. Currently, Itau Unibanco Holding has a market capitalization of $56.80 billion.

ITUB

BTIG Initiates Coverage On Embecta with Neutral Rating

Related Posts

Aprea Unveils Initial Clinical Data On ATRi, ATRN-119, And Pre-Clinical Data On WEE1i, ATRN-1051, At AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

Entrada Therapeutics Announces Clinical Hold On IND Application For ENTR-601-44 In Duchenne Muscular Dystrophy

‘The Big Short’ Star Michael Burry Says SEC Doesn’t Have ‘The Resources Or IQ Point’s To ‘Correctly’ Investigate Coinbase

Here’s How Much $100 Invested In Itau Unibanco Holding 20 Years Ago Would Be Worth Today